Which has the lower trailing P/E, ALNY or WST?

ALNY has the lower trailing P/E: ALNY trades at 36.65 and WST at 45.03. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ALNY or WST?

Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus WST at 5.68%.

Does ALNY or WST pay a bigger dividend?

WST pays a dividend (0.25% yield), while ALNY has no payments in the available dividend history.

Is ALNY or WST more profitable?

WST runs the higher net margin — ALNY at 16.82% versus WST at 16.98%.

How have ALNY and WST total returns compared?

Over the past 10 years, ALNY delivered 11.47% and WST delivered 16.17% annualized total return. Past performance doesn't predict future results.

Alnylam Pharmaceuticals, Inc. (ALNY) vs West Pharmaceutical Services, Inc. (WST)

A side-by-side comparison of Alnylam Pharmaceuticals, Inc. and West Pharmaceutical Services, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 11, 2026. Differences are shown without an overall score or investment verdict.

ALNY

Alnylam Pharmaceuticals, Inc.

$29.60B

$221.20HealthcareDelayed quote: Aug 11, 2026, 4:00 PM EDT

WST

West Pharmaceutical Services, Inc.

$24.73B

$351.37HealthcareDelayed quote: Aug 11, 2026, 4:02 PM EDT

Total return — ALNY vs WST

growth of $100 · dividends reinvested · last 10y

ALNY +192.2% (+11.3%/yr)WST +352.0% (+16.3%/yr)WST compounded faster over this window

ALNY WST

ALNY vs WST: by the numbers

•ALNY is the larger company ($29.60B vs $24.73B market cap).
•ALNY trades at the lower trailing earnings multiple (36.65 vs 45.03 P/E), one valuation lens rather than an overall verdict.
•WST converts more revenue to profit (16.98% vs 16.82% net margin).
•ALNY grew revenue faster over the past five years (47.53% vs 5.68% CAGR).
•WST pays a dividend (0.25% yield), while ALNY has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	ALNY	WST
P/E ratio	36.65	45.03
Forward P/E	32.08	39.38
P/S ratio	6.24	7.55
P/B ratio	22.15	8.40
EV / EBITDA	28.04	28.82
FCF yield	1.81%	1.74%

Profitability

Metric	ALNY	WST
Gross margin	79.72%	36.77%
Operating margin	20.81%	20.64%
Net margin	16.82%	16.98%
ROE	59.67%	18.89%
ROIC	13.74%	13.62%

Dividends

Metric	ALNY	WST
Dividend yield	N/A	0.25%
Payout ratio	N/A	12.88%

Growth (annualized)

Metric	ALNY	WST
Revenue CAGR (5Y)	47.53%	5.68%
EPS CAGR (5Y)	N/A	7.85%
FCF CAGR (5Y)	N/A	8.74%
Total return CAGR (5Y)	0.88%	-3.44%

Frequently asked

Which has the lower trailing P/E, ALNY or WST?: ALNY has the lower trailing P/E: ALNY trades at 36.65 and WST at 45.03. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ALNY or WST?: Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus WST at 5.68%.
Does ALNY or WST pay a bigger dividend?: WST pays a dividend (0.25% yield), while ALNY has no payments in the available dividend history.
Is ALNY or WST more profitable?: WST runs the higher net margin — ALNY at 16.82% versus WST at 16.98%.
How have ALNY and WST total returns compared?: Over the past 10 years, ALNY delivered 11.47% and WST delivered 16.17% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ALNY analysis Full WST analysis Interactive comparison tool

Dig into the metrics

Alnylam Pharmaceuticals P/E ratio West Pharmaceutical Services P/E ratio West Pharmaceutical Services dividend yield Alnylam Pharmaceuticals ROE West Pharmaceutical Services ROE Alnylam Pharmaceuticals operating margin West Pharmaceutical Services operating margin Alnylam Pharmaceuticals revenue growth West Pharmaceutical Services revenue growth Alnylam Pharmaceuticals free cash flow West Pharmaceutical Services free cash flow

Alnylam Pharmaceuticals & West Pharmaceutical Services appear in these rankings

25+ Year Dividend Growers Fastest Revenue Growth Stocks Highest ROE Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 11, 2026.